DelveInsight's "VERZENIO Market Size, Forecast, and Market Insight Report" highlights the details around VERZENIO, which is a ...
Sichuan Kelun-Biotech Biopharma has become the first drugmaker to usher a TROP2-targeted antibody-drug conjugate to ...
TAGRISSO has become a standard treatment due to its strong efficacy in both first-line and adjuvant settings. The growing prevalence of EGFR mutations, a rise in lung cancer diagnoses, and broader ...
During a live event, Alexander I. Spira, MD, PhD, and participants discuss efficacy, adverse events, and sequencing of EGFR-mutated NSCLC treatments.
Daiichi Sankyo is stepping up its interest in RNA therapies, teaming with Nosis Biosciences to design drug candidates capable ...
MedPage Today on MSN3d
De-Escalated Neoadjuvant Chemoimmunotherapy Shows Promise in Early TNBCUse of nivolumab (Opdivo) before chemotherapy was not associated with improved pathologic complete response (pCR) rates among ...
Bangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation ...
The MATTERHORN Phase III trial has demonstrated that a perioperative regimen combining AstraZeneca’s Imfinzi (durvalumab) with FLOT chemotherap ...
AstraZeneca (NASDAQ:AZN) said on Friday that its gastric cancer treatment, IMFINZI, demonstrated a statistically significant ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback